Suggested remit: To appraise the clinical and cost effectiveness of ONS-5010 within its marketing authorisation for treating wet age-related macular degeneration.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6320

Provisional Schedule

Expected publication 11 December 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton

Stakeholders

Companies sponsors Outlook Therapeutics Limited (bevacizumab gamma)
Others Department of Health and Social Care
  NHS England
Patient carer groups Eyecare Trust
  Fight for Sight
  Macular Society
  National Federation of the Blind of the UK
  Network of Sikh Organisations
  Organisation of Blind African Caribbeans
  Retina UK
  Royal National Institute of Blind People
  SeeAbility
  Sense
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Thomas Pocklington Trust
Professional groups Association of Optometrists
  British and Eire Association of Vitreoretinal Surgeons
  British and Irish Orthoptic Society
  British Geriatrics Society
  British Ophthalmic Anaesthesia Society
  College of Optometrists
  Optical Confederation
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Ophthalmologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Bayer (aflibercept)
  Biogen (ranibizumab)
  Genus Pharmaceuticals (ranibizumab)
  Novartis (ranibizumab, brolucizumab)
  Roche (faricimab)
  Teva UK (ranibizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Wales Council for the Blind
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Eyes and Vision group
  Cochrane UK
  Eye Hope
  Genomics England
  Institute of Ophthalmology, University College London
  MRC Clinical Trials Unit
  National Eye Research Centre
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
20 June 2024 Invitation to participate
01 March 2024 - 02 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6320
01 January 2024 In progress. DHSC referral received
23 November 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual